Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Aligos Therapeutics (Nasdaq: ALGS) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026, after the close of U.S. markets.

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026, after the close of U.S. markets. The company is a clinical-stage biotech focused on liver and viral disease therapies.

Argus May 1 session

+1.67% close to close Open Argus

Details

News Market Reaction – ALGS

On May 1, the first trading day after this news, ALGS closed 1.67% above the previous close.

Data tracked by StockTitan Argus for the May 1 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aligos Therapeutics (ALGS) release its Q1 2026 results?

Aligos will report Q1 2026 financial results on May 7, 2026, after U.S. market close. According to the company, the release timing follows standard practice for quarterly disclosures and will be posted after markets close on that date.

How can investors access Aligos Therapeutics (ALGS) Q1 2026 results on May 7, 2026?

Investors can view the results when Aligos publishes its release after market close on May 7, 2026. According to the company, results are typically available via the investor relations website and regulatory filings on the same evening.

Will Aligos Therapeutics (ALGS) provide an earnings call with the Q1 2026 release?

The announcement lists only the Q1 2026 results release on May 7, 2026, after market close. According to the company, details about any accompanying webcast or call will be provided separately if scheduled.

What does the May 7, 2026 timing mean for ALGS stock trading?

Reporting after the close means Aligos posts results after regular trading ends on May 7, 2026. According to the company, this timing lets investors review disclosures overnight before markets reopen the next trading day.

What information will Aligos Therapeutics (ALGS) likely include in the Q1 2026 release?

The company announced only the release date for Q1 2026 results on May 7, 2026, after market close. According to the company, the report typically includes financial results and corporate updates relevant to investors.